These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study. Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654 [TBL] [Abstract][Full Text] [Related]
3. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. He A; Merkel B; Brown JWL; Zhovits Ryerson L; Kister I; Malpas CB; Sharmin S; Horakova D; Kubala Havrdova E; Spelman T; Izquierdo G; Eichau S; Trojano M; Lugaresi A; Hupperts R; Sola P; Ferraro D; Lycke J; Grand'Maison F; Prat A; Girard M; Duquette P; Larochelle C; Svenningsson A; Petersen T; Grammond P; Granella F; Van Pesch V; Bergamaschi R; McGuigan C; Coles A; Hillert J; Piehl F; Butzkueven H; Kalincik T; Lancet Neurol; 2020 Apr; 19(4):307-316. PubMed ID: 32199096 [TBL] [Abstract][Full Text] [Related]
4. Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis. Usta NC; Boz C; Terzi M Clin Neurol Neurosurg; 2023 Jan; 224():107528. PubMed ID: 36446265 [TBL] [Abstract][Full Text] [Related]
5. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes. Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852 [TBL] [Abstract][Full Text] [Related]
6. The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. Hughes S; Spelman T; Trojano M; Lugaresi A; Izquierdo G; Grand'maison F; Duquette P; Girard M; Grammond P; Oreja-Guevara C; Hupperts R; Boz C; Bergamaschi R; Giuliani G; Rio ME; Lechner-Scott J; van Pesch V; Iuliano G; Fiol M; Verheul F; Barnett M; Slee M; Herbert J; Kister I; Vella N; Moore F; Petkovska-Boskova T; Shaygannejad V; Jokubaitis V; McDonnell G; Hawkins S; Kee F; Gray O; Butzkueven H; J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):305-10. PubMed ID: 22205675 [TBL] [Abstract][Full Text] [Related]
7. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden. Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868 [TBL] [Abstract][Full Text] [Related]
8. Pediatric Multiple Sclerosis Severity Score in a large US cohort. Santoro JD; Waltz M; Aaen G; Belman A; Benson L; Gorman M; Goyal MS; Graves JS; Harris Y; Krupp L; Lotze T; Mar S; Moodley M; Ness J; Rensel M; Rodriguez M; Schreiner T; Tillema JM; Waubant E; Weinstock-Guttman B; Hurtubise BF; Roalstad S; Rose J; Casper TC; Chitnis T; Neurology; 2020 Sep; 95(13):e1844-e1853. PubMed ID: 32690790 [TBL] [Abstract][Full Text] [Related]
9. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort. Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792 [TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone: a review of its use in multiple sclerosis. Scott LJ; Figgitt DP CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110 [TBL] [Abstract][Full Text] [Related]